Hepatic and Renal Consequences of Single-Ventricle Physiology Palliated With the Fontan Operation.


Journal

The Canadian journal of cardiology
ISSN: 1916-7075
Titre abrégé: Can J Cardiol
Pays: England
ID NLM: 8510280

Informations de publication

Date de publication:
07 2022
Historique:
received: 21 12 2021
revised: 26 04 2022
accepted: 26 04 2022
pubmed: 8 5 2022
medline: 22 7 2022
entrez: 7 5 2022
Statut: ppublish

Résumé

Over time, long-term survival has dramatically increased for patients with complex congenital heart disease who undergo the Fontan operation. With this increased survival, it has become apparent that such a circulation has important consequences for other organ systems, particularly the liver and kidney. The adverse milieu created by chronic venous hypertension, low cardiac output, and an inflammatory state contribute to the pathologic changes observed in the liver and kidneys over the long term in Fontan patients. The clinical importance of these hepatic and renal comorbidities have only recently begun to be recognized in the context of increasing life expectancy in this population. The objectives of this review are to provide an overview of the pathophysiology of the Fontan circulation and how liver and kidney disease evolve in this setting; to summarize the current evidence base as it relates to the diagnostic approach to liver and kidney disease in Fontan patients; and to discuss the therapeutic approaches to Fontan- associated liver and kidney disease. Given that this is a very active area of research in congenital heart disease, we have identified knowledge gaps and priority research areas to improve the care of Fontan patients. These include establishing the optimal diagnostic tests to detect and track liver and kidney disease change over time, determining which treatable risk factors contribute to the development of liver and kidney disease, and evaluating therapies to prevent or slow progression of liver and kidney disease.

Identifiants

pubmed: 35525398
pii: S0828-282X(22)00279-3
doi: 10.1016/j.cjca.2022.04.022
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1002-1011

Informations de copyright

Copyright © 2022 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Auteurs

Steven L Rathgeber (SL)

Division of Cardiology, British Columbia Children's Hospital, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.

Charmaine Lam (C)

Division of Cardiology, Yasmin and Amir Virani Provincial Adult Congenital Heart Program, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.

Kevin C Harris (KC)

Division of Cardiology, British Columbia Children's Hospital, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.

Jasmine Grewal (J)

Division of Cardiology, Yasmin and Amir Virani Provincial Adult Congenital Heart Program, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: jasmine.grewal@vch.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH